A phase I trial of ATA-190-Autologous in multiple sclerosis

Trial Profile

A phase I trial of ATA-190-Autologous in multiple sclerosis

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs ATA-190 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Nov 2017 According to an Atara Biotherapeutics media release, updated positive results from this trial were presnted at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) in Oct 2017
    • 25 Oct 2017 According to an Atara Biotherapeutics media release, this trial was partially funded by MS Research Australia, MS Queensland and Perpetual Foundation.
    • 25 Oct 2017 Results (n=10) presented in an Atara Biotherapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top